Healthcare ❯Pharmaceuticals

Weight Loss Drugs

Ozempic Wegovy Semaglutide GLP-1 Drugs Mounjaro Novo Nordisk GLP-1 Agonists Zepbound Tirzepatide GLP-1 Medications GLP-1s Clinical Trials GLP-1 Receptor Agonists Survodutide Amycretin Tirzepatide (Zepbound) Challenges Approval and Availability Financial Barriers Cost Reduction and Access Eli Lilly Regulation Market Competition Regulatory Issues Petrelintide GLP-1 Tirzepatide vs. Semaglutide Comparison Clinical Studies Market Availability Market Trends Cost Barriers Effectiveness Studies Prescription Medications GLP Inhibitors Insurance Coverage Obesity Treatments GLP-1 Treatments Incretin Drugs

UK Regulators Warn Weight-Loss Injections Could Undermine Birth Control

Reports of more than 40 unplanned pregnancies prompted the MHRA to advise barrier contraception for women using weight-loss injections.

Delhi High Court Bars Dr. Reddy’s and OneSource from Marketing Semaglutide

Novo Nordisk CEO Steps Down Following Share Price Collapse

UK Nears One Million Users of Weight-Loss Jabs as New Benefits and Risks Emerge

Eli Lilly Expands Legal Fight Against Compounded GLP-1 Drugs

Hims & Hers Expands Weight-Loss Offerings with New Medications

Novo Nordisk Faces Investor Turmoil as Wegovy Sales and Market Share Decline

Rising Use of Ozempic Raises Health, Ethical, and Social Concerns

Poll Shows Americans Divided Over Weight-Loss Drugs for Obesity Treatment

U.S. Obesity Rates Decline for First Time in Over a Decade

Expanded Access to Weight-Loss Drugs Could Save Over 40,000 Lives Annually

Senator Warren Urges FTC to Scrutinize Novo Holdings' $16.5B Catalent Acquisition

Eli Lilly's Weight-Loss Drugs Drive Record Q2 Revenue Surge

Ozempic Shows Promise Beyond Diabetes Treatment

Eli Lilly's Mounjaro Outperforms Novo Nordisk's Ozempic in Weight Loss Study

Weight-Loss Drug Tirzepatide Shows Promise for Treating Sleep Apnea

Zealand Pharma's Petrelintide Shows Promising Results in Early Weight Loss Trial

Weight-Loss Drug Market Heats Up as Prices Drop and New Treatments Emerge

Eli Lilly's Q1 Earnings Surge on Strong Zepbound and Mounjaro Sales

Eli Lilly Faces Zepbound Shortage, Impacting Weight Loss and Diabetes Patients